How Health Systems Are Operationalizing Third-Party AI Assessments

If a health system buys outside AI, it needs one review path from intake to post-launch checks. That’s the core point here.

I’d boil the article down to this:

• Put AI vendor review inside vendor risk and cybersecurity
• Tier each tool by patient care impact, PHI use, and EHR access
• Use one intake form and one inventory for every AI request
• Match review depth to risk
• Set contract terms for retraining, data use, and incident notice
• Test locally before launch
• Watch drift, safety events, and vendor changes after launch
• Give a committee clear stop, approve, and escalation rights

The article also makes one thing plain: contract signature is not the same as go-live approval. A tool may pass procurement and still fail local testing, workflow checks, or safety review.

A few facts stand out:

• High-risk tools include AI used in triage, diagnosis, imaging, and care decisions
• Reviews should cover more than security controls; they should also check data flows, bias risk, retraining rules, and model change notices
• The piece points to ONC HTI-1 disclosure rules and HSCC guidance as a base for health system review
• The suggested lifecycle has 5 main steps: tiering, intake, due diligence, validation, and governance

Here’s the short version in one view:

Bottom line: the article argues that health systems should treat outside AI like a vendor risk issue plus a patient safety issue, with named owners, documented gates, and scheduled re-checks.

That’s the simple frame I’d use before reading the rest.

Navigating AI Vendor Risks: Essential Considerations for Healthcare Organizations

1. Define AI Use Cases and Risk Tiers Before the Review Begins

Before you send a vendor questionnaire or draft a contract, nail down one basic point: what does this AI tool do, and what happens if it gets it wrong? That answer should shape the depth of review, the approval path, and what you watch after go-live.

Classify Each AI Tool by Clinical Impact, Data Sensitivity, and Workflow Role

Start by documenting the use case, intended users, data sources, system connections, the tool’s role - advisory, automated, or autonomous - and rollout scope before the review starts. Those fields should line up with NIST AI RMF categories like context, intended use, and affected stakeholders.

Three factors matter most when you classify the tool: clinical impact, data sensitivity, and EHR integration depth.

Clinical impact tells you how directly the tool can affect patient care. At the low end, you might have a tool that drafts non-clinical staff messages. In the middle, there’s decision support that suggests diagnostic codes or flags possible drug interactions, but still depends on clinician review. At the high end, think sepsis alerts or stroke-detection algorithms that shape real-time care decisions.

EHR integration depth adds another risk layer. Read-write EHR access, such as placing orders or updating notes, carries more risk than read-only analytics, even when both handle PHI.

Data sensitivity is the third screen. Reviewers should confirm:

• Whether the tool uses identifiable PHI, a limited data set, or fully de-identified data under HIPAA
• Which data elements it uses
• Whether data is stored, processed, or sent to external cloud services or third-party environments
• Whether outputs could expose identity or sensitive data

Lower-risk tools may rely on de-identified or synthetic data inside a contained environment with no outside sharing. Tools that move identifiable PHI outside the system should go to deeper privacy, security, and legal review.

Match Risk Tiers to Review Depth and Approval Requirements

Use this tiering model to set review depth and approval needs.

Once the tier is set, it should determine who reviews the request and how much proof they need to see. The logic is simple: map the use, measure possible harm, then manage it by tier. That lines up with the Map–Measure–Manage approach and with FDA Software as a Medical Device (SaMD) thinking, where scrutiny scales with how critical the clinical function is.^[2][3]

Assign Accountable Owners for Each Proposed AI Deployment

Don’t let a proposal move ahead without named owners. Every proposal should have:

• A business owner who defines the use case and owns operational outcomes
• A clinical owner, for any tool that touches clinical workflows, who is accountable for safety and appropriateness
• A security lead who signs off on technical controls and integration risk
• A privacy and compliance reviewer who covers HIPAA, data-sharing arrangements, and regulatory exposure
• A procurement lead who turns risk requirements into contract terms

Put those names in the intake record so security, privacy, clinical, and procurement teams know who approves what and who handles escalations.

Once the tool is tiered and owners are assigned, route it into the central intake and due diligence workflow.

2. Build a Central Intake and Due Diligence Workflow for External AI Vendors

Section 1 set the risk tier. This section puts that tier to work through one intake, review, and inventory process. Once a tool is tiered and owners are named, every request should go through the same intake path.

Use a Standardized Intake Form to Capture What Reviewers Need

Use one intake form to collect the use case, workflow role and system integration, data flows, hosting model and architecture, model type, and governance flags.

Each field has a clear job.

Use case and clinical context show who will use the tool and whether its outputs shape care decisions. Workflow role and system integration show which systems connect and how data moves through APIs, HL7/FHIR interfaces, or file transfers. Data flows and PHI handling confirm which data types are involved, whether data leaves the organization’s network, and whether any sub-processors receive it. Hosting model and architecture record whether the tool runs on-premises, in a single-tenant cloud, or in a multi-tenant SaaS setup, plus the cloud provider and U.S. region. Model type shows whether the tool is predictive, NLP, a large language model, or rules-based. It should also include key performance metrics such as sensitivity, specificity, or AUROC, along with the vendor’s retraining approach. Governance flags note whether the tool falls under medical device software or tools with FDA or URAC status and whether a BAA is required.

This keeps incomplete submissions from slowing down review. The finished form should route the request once, not force teams to chase the same facts in separate reviews.

Route Requests Through a Multidisciplinary Review Path

When the intake form is complete, routing becomes rule-based. The risk tier assigned in Section 1 decides which teams get the request.

Security and IT review every request. Privacy reviews PHI use. Clinical leadership reviews tools that affect diagnosis, treatment, or triage. Low-risk administrative tools can move through an expedited path that covers procurement, IT security, and compliance only.

Before a pilot launches, require sign-off on limits, monitoring, and incident response. Before production, require validated performance and finalized contract controls. Reassess after any material change in the model, data sources, or vendor controls. If reviewers find missing documentation or safety concerns, escalate to the AI governance committee. That group can pause pilots, require independent testing, or refer the matter to legal if regulatory duties may be at risk.

Maintain an AI Inventory and Assessment Record

Every third-party AI tool under review or already in use should have a record in one central inventory.

Each record should include:

• Vendor name
• Product name and version
• Use case description
• Department or service line
• Business owner
• Technical owner
• Clinical champion for patient-impacting tools
• Risk tier
• Deployment status: proposed, in review, pilot, limited production, systemwide, or retired
• Contract start and end dates
• Linked security questionnaires and legal reviews
• Any unresolved findings, plus responsible owners and due dates

Centralized intake and reassessment can shorten review cycles and improve visibility with the same staff.

That record becomes the source of truth for security, privacy, and contract review. From there, the next control defines what those reviews must cover.

sbb-itb-535baee

3. Standardize AI-Specific Security, Compliance, and Contract Reviews

Once intake is done, use the risk tier to decide how deep the security, compliance, and contract review should go. This review should look at security, privacy, compliance, and contract terms as one package.

Go Beyond the Standard Security Questionnaire

A standard security questionnaire usually asks whether a vendor has firewalls, encryption, and an incident response plan. That’s a good start. For AI tools, it’s nowhere near enough.

The review should cover how the AI system handles data from start to finish: what data it takes in, how it stores prompts and outputs, whether patient data is used to retrain the model, and how long data is kept. Ask directly whether vendor administrators can view patient data, how that access is logged, and whether audit logs track prompts, outputs, overrides, and access events.

That review should also reach past the main vendor to its model providers and other subprocessors. Ask vendors to name their key subprocessors, explain what data each one gets, and spell out what happens if a subprocessor changes its terms or goes offline.^[1]

For tools tied to clinical workflows, the questionnaire should also ask how the vendor tests for bias across demographic groups, how model limits are documented, and whether the tool gives users uncertainty signals before they act on an output.

Tailor Questionnaires and Evidence Requests by Risk Tier

Use the tier to set how much proof reviewers need. The risk tier assigned in Section 1 should directly control the depth of evidence required.

For high-risk tools, policy statements alone don’t cut it. Reviewers should ask for concrete artifacts like a security architecture diagram, penetration test summaries, validation results on representative patient populations, and proof of bias testing across key demographic groups.^[5][9] AI-assisted triage can help move review along, but the final decision stays with people.

Set Contract Controls That Support Oversight After Signature

The contract is where oversight duties become enforceable. Legal and compliance teams should treat the AI vendor agreement as an oversight document, not just onboarding paperwork.

Prohibit the use of patient data for training or retraining without written permission.^[4][8] Contracts should also set breach notification timelines, require vendor help during incident investigations, and give the health system audit rights that reach AI-specific records such as data lineage records, model cards, training logs, and penetration testing summaries.^[6][7]

It also makes sense to require advance notice before retraining, fine-tuning, or other material model changes, so the health system can revalidate the tool before release. The contract should include the right to suspend use if the vendor misses performance, compliance, or security requirements, along with clear remediation duties if a safety or security issue appears after deployment.^[4][6][7][8]

Once those contract controls are in place, the next step is local validation before production, followed by monitoring after launch.

4. Validate Before Go-Live and Monitor After Deployment

Once contract controls are set, the next step is local validation in your own environment. Contract approval is not go-live approval. Local validation and workflow testing show whether the tool actually works where you plan to use it.

Run Local Validation and Workflow Testing Before Production Use

Vendor testing doesn't prove local fit. For every higher-risk tool, use the same validation sequence so the review stays repeatable: retrospective testing on local historical data, silent mode, shadow mode, and then a limited pilot with predefined success criteria. Results can vary a lot from one site to another, which is why local validation and workflow fit matter before launch.

Before go-live, document the tool's known limitations, intended use cases, failure modes, and the situations where clinicians should rely on it or override it. Store those limits with the validation record.

Apply Deployment Controls for Integration, Access, and Change Management

If validation passes, lock down production access before rollout. Keep test and production environments strictly separate. Use role-based access, approval gates, and change tickets for any production-facing update. For higher-risk tools, define a rollback plan before launch so the team can disable or revert the AI fast if something goes wrong after go-live.

Treat every material update as a controlled release. That means advance notice from the vendor, records showing what changed, and sign-off from clinical, IT, security, and compliance reviewers before any update reaches production. If the vendor uses continuous learning or frequent updates, spell out up front which changes are material enough to trigger a formal review cycle.

Set Up Monitoring, Incident Response, and Periodic Reassessment

Post-deployment monitoring should continue over time, with clear checkpoints. Track performance drift, subgroup performance changes, input-data quality issues, downtime, safety events, and changes in how the tool handles or transmits data. Day-to-day metrics matter too, including:

• usage volume
• alert override rates
• false positive and false negative rates
• clinician feedback

Higher-risk tools need tighter thresholds and shorter review intervals.

AI-related incidents need their own response path. Define who can disable the tool, how clinicians are notified, how affected cases are reviewed, and when the vendor is escalated. For higher-risk tools, the incident plan should include patient safety reporting, rollback steps, and clear criteria for temporary or permanent suspension. Passive surveillance isn't enough. Set explicit escalation triggers, and make sure those triggers feed straight into the reassessment cycle.

Reassessment should be both scheduled and event-driven. Any major event - a model update, a workflow change, a safety incident, or signs of performance degradation - should trigger an immediate review. Censinet AI can centralize validation, monitoring, and reassessment in one auditable workflow. But that only works if ownership, escalation, and metrics are clearly defined in governance.

The next step is governance: who approves, who escalates, and what gets reported.

5. Governance, Program Metrics, and a Practical Rollout Plan

Define Committee Roles, Escalation Paths, and Approval Thresholds

Once monitoring is live, governance decides who can act on what the program finds. It spells out who can approve, pause, or retire a tool when risk shifts.

HSCC recommends that large health systems set up a board-reporting AI Governance Committee with clinical AI, cybersecurity, ethics, and vendor-risk working groups.^[11]

That committee sets risk appetite and policy. Cybersecurity handles security due diligence, integration, and incident response. Compliance and privacy handle HIPAA and data-use review. Clinical leadership handles workflow fit, bias, and oversight. Legal handles contract and liability terms. Procurement blocks onboarding and renewal until intake and tiering are done.^[11] In practice, this committee becomes the place where unresolved findings, high-risk approvals, and reassessment triggers land.

Escalation thresholds should be written down, not left to guesswork. Each tier should map to a clear decision path:

• Tier 1 tools can be approved by the manager and IT security.
• Tier 2 tools need business-owner, security, privacy, and procurement sign-off, with committee notice if unresolved high-risk findings appear.
• Tier 3 tools - any tool that affects diagnosis, treatment, or triage - need full committee approval, plus sign-off from the CISO, privacy officer, CMIO, and legal before go-live.

Any tool used in patient triage should trigger escalation, no matter how the vendor labels it. The policy should also name emergency stop authority so a tool can be paused fast if an incident happens.^[11]

Any unapproved AI tool that touches PHI, clinical decisions, or EHR integration should go through intake before contracting or piloting. Health systems should also scan SaaS and EHR app usage to spot tools that slipped past the process. Stop criteria should be set in advance for safety incidents, bias, FDA safety communications, and vendor breaches, along with a rollback path so teams can move back to a safe workflow without chaos.^[11]

Track the Metrics That Show Whether the Program Is Working

Track governance metrics across the full lifecycle.^[12]

Start with intake volume and mix each quarter: total requests, distribution by risk tier, and breakdown by department. Then pair that with time to review by tier - median and 90th percentile cycle time from completed intake to decision. That makes bottlenecks easier to spot before they turn into the norm.

On the risk side, watch open findings by severity and age. Flag anything still unresolved after 30, 60, or 90 days. Track the share of high-severity findings with active mitigation plans, and count contract exceptions from standard data protection or liability clauses.

For ongoing oversight, track reassessment completion rate - the percentage of AI vendors reassessed on schedule - and the number of new deployments that bypassed the approved intake process. After deployment, count and sort AI-related incidents, including safety events, privacy breaches, availability outages, and rollbacks.

Those metrics should guide how the program expands, without derailing the review work already in motion.

Conclusion: The Core Controls Every Health System Should Put in Place

Every part of this guide comes back to the same core setup: risk-tier early, centralize intake, standardize due diligence, require governance checkpoints, validate locally, and monitor all the time.

The table below shows how each checkpoint cuts specific risks:

Censinet RiskOps™ and Censinet AI™ support this model by centralizing intake, routing assessments to the right reviewers, managing questionnaires and evidence, and providing a real-time AI risk dashboard that keeps governance committees informed. Their routing and orchestration capability pulls intake, evidence collection, and escalation into one path across GRC teams.

A phased rollout makes this easier to manage. Start with one or two high-visibility tools. Then require intake for all PHI-touching or EHR-integrated tools, stand up the governance committee, report metrics, and expand across the enterprise. As the program grows, fold AI screening into procurement and ITSM workflows. Change management should include executive sponsorship, clear policies, and regular communication about why this exists: patient safety and regulatory defense.

The AMA's guidance is clear that governance policies and oversight mechanisms should be in place before adopting generative AI tools in care delivery.^[10][12] Health systems that put this structure in place now - before their AI vendor portfolio gets larger - will be in a much stronger position when regulators, auditors, or patients ask how these tools are being managed.

FAQs

Who should own the AI review process?

Each AI tool needs a named owner and clear decision rights. But that ownership shouldn't live with just one team. A multidisciplinary AI governance committee should guide the process and keep everyone aligned.

That matters because AI touches a lot of parts of the business at once. Clinical, IT, security, privacy, legal, compliance, procurement, and operations teams should each make decisions in their own area. Put simply: the people closest to the risk and day-to-day work should have a say.

A RACI matrix helps keep accountability clear from procurement through retirement. It spells out who is responsible, who approves, who needs to be consulted, and who should stay informed, so decisions don't fall through the cracks.

How do we decide which AI tools need the deepest review?

Use a risk-based tiering process before procurement. Put each AI tool into a central risk register, and track its intended use, data provenance, and clinical impact.

Then sort each use case into a risk tier based on two things:

• how much PHI it handles
• how much it could affect patient care or day-to-day operations

Tools that handle PHI and shape diagnosis, treatment, or escalation decisions need the deepest review. Lower-risk administrative tools may need a lighter check.

This helps teams avoid treating every AI tool the same way. A scheduling assistant and a clinical decision support tool don’t carry the same level of risk, so they shouldn’t go through the exact same review path either.

What should trigger a re-review after go-live?

After go-live, any material change to the AI system should trigger a re-review. That means things like model updates, retraining, or any change that affects intended use, performance, or safety.

Monitoring signals should also kick off a re-review. Common triggers include:

• Model drift
• Adverse performance events
• Bias incidents
• Data governance changes
• New subprocessors
• Audit report status changes

Regular reviews matter too. High-risk vendors should be reviewed quarterly, while lower-risk vendors should be reviewed once a year.

Related Blog Posts

• Healthcare AI Data Governance: Privacy, Security, and Vendor Management Best Practices
• The Third-Party AI Problem: Vendor Risk in an Algorithm-Driven World
• Leading Through Uncertainty: Executive Decision-Making in Healthcare AI
• The Hidden Third Parties Inside Healthcare AI